Expanding Therapeutic Options in Liver Oncology in Romania
The introduction of Yttrium-90 (Y-90) radioembolization marks a significant step in diversifying treatment options for liver cancer in Romania, particularly for patients with advanced stages of the disease.
The performance of the first local intervention highlights the capacity of leading medical centers to integrate highly specialized procedures and support multidisciplinary approaches in oncology. This development reflects a gradual alignment with international standards in the treatment of complex cancers.
Given that a significant number of patients could benefit from this technology, initiatives to include it in the reimbursement system become essential for ensuring sustainable access to innovative treatments. The high costs of the procedure underscore the importance of financing mechanisms adapted to the new realities of the medical field.
The development and integration of such therapeutic solutions confirm the direction toward modernization of the healthcare system and the need for strong partnerships to facilitate access to innovation.
Torus Pharma contributes by connecting advanced medical technologies with the local market, supporting access to innovative therapies and the development of effective solutions in complex therapeutic areas.
